Intervention

epirubicin hydrochloride

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 49 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials49

Recruiting0

Common conditions19

Lead sponsors shown15

Clinical trials

49 shown

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer PatientsNCT04418154 · 2020-06-09

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast CancerNCT02315196 · 2015-02-25

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast CancerNCT01880385 · 2011-03-01

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast CancerNCT01093235 · 2009-04-01

Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer PatientsNCT00820547 · 2009-01-01

Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By SurgeryNCT00963729 · 2008-09-01

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast CancerNCT00629278 · 2007-12-01

Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30NCT00753207 · 2007-10-01

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast CancerNCT00630032 · 2007-09-01

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast CancerNCT00872625 · 2007-04-01

Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast CancerNCT00516425 · 2007-01-01

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By SurgeryNCT00398489 · 2006-10-01

Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast CancerNCT00379015 · 2006-01-01

Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryNCT00301925 · 2005-12-16

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast CancerNCT00288002 · 2005-01-01

Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast CancerNCT00070278 · 2005-01-01

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate CancerNCT00096304 · 2004-06-08

Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast CancerNCT00309920 · 2004-01-01

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast CancerNCT00066443 · 2003-11-03

Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By SurgeryNCT00311636 · 2003-09-01

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast CancerNCT00072319 · 2003-08-01

Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast CancerNCT00645866 · 2003-04-01

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast CancerNCT00433420 · 2003-04-01

ACTIVE_NOT_RECRUITING

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast CancerNCT00053911 · 2002-11-01

Combination Chemotherapy in Treating Women With Stage I Breast CancerNCT00055679 · 2002-08-01

Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast CancerNCT00253500 · 2002-06-01

Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone SurgeryNCT00039546 · 2001-08-01

Combination Chemotherapy in Treating Women With Breast CancerNCT00047099 · 2001-08-01

Gemcitabine and Epirubicin in Treating Patients With Malignant MesotheliomaNCT00017186 · 2001-07-01

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast CancerNCT00017095 · 2001-03-01

Combination Chemotherapy in Treating Women With Resected Breast CancerNCT00033683 · 2001-02-01

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast CancerNCT00014222 · 2000-12-04

Combination Chemotherapy in Treating Women With Stage II or Stage III Breast CancerNCT00005581 · 2000-06-01

Combination Chemotherapy Before Surgery in Treating Women With Breast CancerNCT00008034 · 2000-02-01

Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast CancerNCT00004237 · 1998-10-01

Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast CancerNCT00003893 · 1998-07-01

Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)NCT01031030 · 1997-11-01

Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung CancerNCT00011921 · 1997-09-01

Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast CancerNCT00010140 · 1997-08-01

Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV InfectionNCT00003262 · 1997-05-01

Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast CancerNCT00002953 · 1996-12-01

Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast CancerNCT00003012 · 1996-10-01

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast CancerNCT00002866 · 1996-08-12

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast CancerNCT00002784 · 1996-06-01

Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung CancerNCT00003606 · 1996-03-01

Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast CancerNCT00003577 · 1996-03-01

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast CancerNCT00002870 · 1994-12-01

Tamoxifen in Treating Women With High-Risk Breast CancerNCT00002542 · 1993-07-20

Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast CancerNCT00002529 · 1993-05-01

Common conditions

Breast Cancer41 Lung Cancer2 Cardiac Toxicity1 Estrogen Receptor-negative Breast Cancer1 HER2-negative Breast Cancer1 Inflammatory Breast Cancer1 Lymphoma1 Malignant Mesothelioma1 Neutropenia1 Perioperative/Postoperative Complications1 Progesterone Receptor-negative Breast Cancer1 Prostate Cancer1 Stage IIA Breast Cancer1 Stage IIB Breast Cancer1 Stage IIIA Breast Cancer1 Stage IIIB Breast Cancer1 Stage IIIC Breast Cancer1 Triple Negative Breast Cancer1 Triple-negative Breast Cancer1

Leading sponsors

UNICANCER 6 NCIC Clinical Trials Group 4 Cambridge University Hospitals NHS Foundation Trust 2 ETOP IBCSG Partners Foundation 2 European Organisation for Research and Treatment of Cancer - EORTC 2 Institute of Cancer Research, United Kingdom 2 IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 2 University Hospital Birmingham 2 Alliance for Clinical Trials in Oncology 1 Association Tunisienne de lutte Contre le Cancer 1 Azienda Ospedaliero-Universitaria di Modena 1 Cancer Research Campaign Clinical Trials Centre 1 Cancer Trials Ireland 1 Case Comprehensive Cancer Center 1 Centre Antoine Lacassagne 1

Trial status mix

COMPLETED29

UNKNOWN16

ACTIVE_NOT_RECRUITING2

TERMINATED2

Phase mix

PHASE329

PHASE213

PHASE17

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.